MX2018010796A - Vacunas de circovirus porcino quimerico tipo 2 (pcv2). - Google Patents

Vacunas de circovirus porcino quimerico tipo 2 (pcv2).

Info

Publication number
MX2018010796A
MX2018010796A MX2018010796A MX2018010796A MX2018010796A MX 2018010796 A MX2018010796 A MX 2018010796A MX 2018010796 A MX2018010796 A MX 2018010796A MX 2018010796 A MX2018010796 A MX 2018010796A MX 2018010796 A MX2018010796 A MX 2018010796A
Authority
MX
Mexico
Prior art keywords
pcv2
porcine circovirus
circovirus type
vaccines
genotypes
Prior art date
Application number
MX2018010796A
Other languages
English (en)
Inventor
Jin Meng Xiang-
R Matzinger Shannon
M Beach Nathan
Original Assignee
Virginia Tech Intellectual Properties Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virginia Tech Intellectual Properties Inc filed Critical Virginia Tech Intellectual Properties Inc
Publication of MX2018010796A publication Critical patent/MX2018010796A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2750/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Las composiciones y los métodos de vacuna se describen para proporcionar inmunidad a los genotipos de circovirus porcino de tipo dos (PCV2) que incluyen la administración de un polipéptido de cápsida de PCV2 recombinante que comprende epítopos antigénicos de las cápsidas de múltiples genotipos de PCV2; en otras modalidades, se proporciona un circovirus porcino quimérico recombinante para usar como una vacuna que combina la cadena principal no patógena del circovirus porcino tipo 1 (PCV1) con las secuencias que codifican un polipéptido de cápsida PCV2 que comprende epítopos antigénicos de las cápsidas de múltiples genotipos PCV2.
MX2018010796A 2016-03-07 2017-03-03 Vacunas de circovirus porcino quimerico tipo 2 (pcv2). MX2018010796A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662304596P 2016-03-07 2016-03-07
PCT/IB2017/000966 WO2017187277A2 (en) 2016-03-07 2017-03-03 Chimeric porcine circovirus type 2 (pcv2) vaccines

Publications (1)

Publication Number Publication Date
MX2018010796A true MX2018010796A (es) 2019-01-14

Family

ID=60160159

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018010796A MX2018010796A (es) 2016-03-07 2017-03-03 Vacunas de circovirus porcino quimerico tipo 2 (pcv2).

Country Status (11)

Country Link
US (1) US20190091320A1 (es)
EP (1) EP3426293A4 (es)
JP (1) JP2019507784A (es)
KR (1) KR20190017725A (es)
CN (1) CN109195623A (es)
AU (1) AU2017257302A1 (es)
BR (1) BR112018068078A2 (es)
CA (1) CA3016374A1 (es)
EA (1) EA201800494A1 (es)
MX (1) MX2018010796A (es)
WO (1) WO2017187277A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220265808A1 (en) * 2019-07-26 2022-08-25 Ndsu Research Foundation A porcine circovirus type 2 (pcv2) vaccine
BR112022003137A8 (pt) * 2019-08-20 2022-09-27 Km Biologics Co Ltd Vacina de vlp de circovírus porcino de tipo 2
PE20211141A1 (es) * 2019-12-19 2021-06-25 Farm Veterinarios S A C Salmonella enteritidis recombinante y su uso como vacuna porcina
CN111253494B (zh) * 2020-03-10 2022-04-26 天康制药(苏州)有限公司 猪***病毒和猪轮状病毒的融合蛋白、类病毒颗粒和疫苗及制备方法
CN111892659A (zh) * 2020-07-20 2020-11-06 武汉科前生物股份有限公司 一种嵌合型猪圆环病毒PCV1-2d疫苗及其制备方法和应用
CN113896771B (zh) * 2020-08-26 2023-10-27 中国农业科学院兰州兽医研究所 一类促进猪机体产生非洲猪瘟病毒抗原特异性免疫应答的多肽及其应用
CN111925417B (zh) * 2020-08-26 2021-11-26 中国农业科学院兰州兽医研究所 一类促进猪机体产生广谱性免疫应答的多肽及其应用
CN113740528A (zh) * 2020-12-08 2021-12-03 山东畜牧兽医职业学院 一种猪传染性胃肠炎病毒抗体检测试剂盒
CN112294953A (zh) * 2020-12-31 2021-02-02 北京科牧丰生物制药有限公司 一种pcv2型杆状病毒载体、猪肺炎支原体、副猪嗜血杆菌三联灭活疫苗及制备方法
KR102646305B1 (ko) * 2021-03-04 2024-03-13 주식회사 이노백 돼지 마이코플라스마균 및 돼지 써코바이러스 감염 예방을 위한 다가 백신 조성물
WO2022186661A1 (ko) * 2021-03-04 2022-09-09 주식회사 이노백 돼지 마이코플라스마균 및 돼지 써코바이러스 감염 예방을 위한 다가 백신 조성물
CN113355292B (zh) * 2021-06-04 2024-02-06 天康制药股份有限公司 一种猪圆环病毒基因改造型弱毒株、构建方法及其应用
CN114487396A (zh) * 2021-12-20 2022-05-13 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 用于检测猪圆环病毒2型的红色乳胶微球免疫层析试纸条及其制备方法和应用
CN114805501B (zh) * 2022-03-24 2024-06-25 中牧实业股份有限公司 一种猪圆环病毒2型抗原组合物及其在抗原定量方法中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7276353B2 (en) * 2001-12-12 2007-10-02 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
US20090017064A1 (en) * 2007-07-10 2009-01-15 Wyeth Methods and Compositions for Immunizing Pigs Against Porcine Circovirus
EP3639852A1 (en) * 2010-03-16 2020-04-22 Virginia Tech Intellectual Properties, Inc. Live attenuated chimeric porcine circovirus vaccine
KR102319843B1 (ko) * 2013-09-25 2021-10-29 조에티스 서비시즈 엘엘씨 Pcv2b 분지형 백신 조성물 및 사용 방법
EA035265B1 (ru) * 2013-10-02 2020-05-21 Бёрингер Ингельхайм Энимал Хелс Ю-Эс-Эй Инк. Вариант белка opc2 pcv2 и содержащие его вирусоподобные частицы

Also Published As

Publication number Publication date
KR20190017725A (ko) 2019-02-20
EA201800494A1 (ru) 2019-07-31
EP3426293A2 (en) 2019-01-16
WO2017187277A2 (en) 2017-11-02
CA3016374A1 (en) 2017-11-02
EP3426293A4 (en) 2019-10-30
CN109195623A (zh) 2019-01-11
JP2019507784A (ja) 2019-03-22
BR112018068078A2 (pt) 2019-01-08
US20190091320A1 (en) 2019-03-28
AU2017257302A1 (en) 2018-09-27
WO2017187277A3 (en) 2017-12-14

Similar Documents

Publication Publication Date Title
MX2018010796A (es) Vacunas de circovirus porcino quimerico tipo 2 (pcv2).
MX2016004063A (es) Variante de la proteina pcv2 orf2 y particulas similares al virus compuestas por esta.
MY187462A (en) Modified virus-like particles of cmv
PH12016500473B1 (en) Pcv2b divergent vaccine composition and methods of use
CO2019014677A2 (es) Vectores de poxvirus que codifican antígenos del virus de inmunodeficiencia humana (vih), y métodos de uso de los mismos
MX2013004159A (es) Proteina vp6 de la capside de norovirus y de rotavirus para el uso como vacuna combinada.
MX2016010954A (es) Construcciones de proteina superficial ubicua a2 y usos de las mismas.
MX350274B (es) Vacunas para hsv-2.
EP2949341A4 (en) RECOMBINANT ANTIGENS OF SWINE CIRCOVIRUS-2 (PCV-2) FOR VACCINATE FORMULATIONS, DIAGNOSIS KIT AND USE THEREOF
EA201491123A1 (ru) Субъединичная вакцина против цирковируса свиней типа 2 (pcv2)
CL2015002741A1 (es) Composiciones y métodos para aumentar la respuesta inmune contra patógenos entéricos
MX2018004016A (es) Vacunas de particulas tipo virus (vlp) contra el parvovirus canino (cpv) y sus usos.
WO2014150822A3 (en) Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use
NZ703297A (en) Reassortant btv and ahsv vaccines
EA201892735A1 (ru) Состав вакцины против hiv
MY179251A (en) Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development
MX2021012311A (es) Variantes de capsides de aav para liberacion intravitrea.
MX2020003591A (es) Constructos del virus recombinante no patogenico de la enfermedad de marek que codifica multiples antigenos heterologos.
WO2018066999A3 (en) Chimeric enterovirus virus-like particles
MX2016000235A (es) Metodos y composiciones para vacunas del virus del dengue.
PH12017501100B1 (en) Recombinant swinepox virus and vaccines
BR112017004181A2 (pt) ?gene, vetor, célula hospedeira, partículas similares a vírus, vacina para vírus de papiloma humano, composição imunogênica, adjuvante, método para o preparo de uma vacina de papiloma humano, proteína de capsídeo principal e proteína hpv l1?
MX2011004219A (es) Vacuna contra el virus de la peste equina africana.
PH12018502576A1 (en) Multivalent recombinant spv
EA201990719A1 (ru) Новые промоторы